Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
Belite Bio will present oral topline results from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1 at the Retina China 2026 symposium in Nanjing. The presentation, led by Dr. Ruifang Sui, highlights a 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo, with a favorable safety profile.
Key figures
- Drug Name
- tinlarebant
- Phase Of Trial
- Phase 3
- Lesion growth reduction
- 35.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.